These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7919239)

  • 21. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
    Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relation between the duration of the chronic phase of chronic myeloid leukemia and total dose of busulfan in the first year of the treatment].
    Hellmann A; Koberda J; Baran W
    Acta Haematol Pol; 1990; 21(1):60-5. PubMed ID: 2260409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T; Bumm T; Otto S; Al-Ali HK; Kovacs I; Krug D; Köhler T; Krahl R; Niederwieser D; Deininger MW
    Haematologica; 2004 Jan; 89(1):49-57. PubMed ID: 14754606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation.
    Gratwohl A; Hermans J; Niederwieser D; Frassoni F; Arcese W; Gahrton G; Bandini G; Carreras E; Vernant JP; Bosi A
    Bone Marrow Transplant; 1993 Nov; 12(5):509-16. PubMed ID: 8298562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
    López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
    Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
    J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
    Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
    Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
    Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia.
    Rodriguez J; Cortes J; Talpaz M; O'Brien S; Smith TL; Rios MB; Kantarjian H
    Clin Cancer Res; 2000 Jan; 6(1):147-52. PubMed ID: 10656443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
    Soupir CP; Vergilio JA; Dal Cin P; Muzikansky A; Kantarjian H; Jones D; Hasserjian RP
    Am J Clin Pathol; 2007 Apr; 127(4):642-50. PubMed ID: 17369142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivariate analysis of prognostic factors in chronic myelogenous leukemia.
    Jootar S; Chuncharunee S; Ongphiphaphadhanakul B; Atichartakarn V
    J Med Assoc Thai; 1990 Dec; 73(12):662-9. PubMed ID: 2086713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Observation of long-term therapeutic outcome in chronic granulocytic leukemia].
    Liu B; Wang Y; Hao C; Liu Y; Qian L
    Zhonghua Xue Ye Xue Za Zhi; 2001 Feb; 22(2):61-3. PubMed ID: 11877049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The prognostic significance of the differential blood count in patients with chronic myeloid leukemia].
    Zankovich R; Schilling H; Thiele J; Kvasnicka HM; Diehl V
    Med Klin (Munich); 1989 Aug; 84(8):373-7. PubMed ID: 2796866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.